Study Examining the PROMUS Element Everolimus-eluting Stent in Multi-center Coronary Intervention of Complex Arterial Lesion Subsets (SPECIALIST)

August 21, 2012 updated by: The PCI Guideline Research Society
Randomized trials have demonstrated an excellent safety and efficacy profile for the chromium everolimus-eluting stent. The platinum chromium everolimus-eluting sten (PtCr-EES) uses the identical antiproliferative agent and polymer but with a novel platinum chromium scaffold designed for enhanced deliverability, vessel conformability, side-branch access, radiopacity, radial strength, and fracture resistance. However, the efficacy of the PtCr-EES for complex coronary artery diseases subsets such as chronic total occlusion, bifurcation lesion, left main trunk disease, and small vessel diseases is still unknown.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

800

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Japan
      • Fukuoka, Japan, 810-0001
        • Not yet recruiting
        • Saiseikai Fukuoka General Hospital
        • Contact:
          • Takeshi Serikawa
        • Principal Investigator:
          • Takeshi Serikawa, MD
      • Kumamoto, Japan, 861-4193
        • Not yet recruiting
        • Saiseikai Kumamoto Hospital
        • Contact:
          • Eiji Taguchi
        • Principal Investigator:
          • Eiji Taguchi, MD
    • Aichi
      • Nagakute, Aichi, Japan, 480-1195
        • Not yet recruiting
        • Aichi Medical University Hospital
        • Contact:
          • Hiroaki Takashima
        • Principal Investigator:
          • Hiroaki Takashima, MD
      • Toyohashi, Aichi, Japan, 441-8530
        • Recruiting
        • Toyohashi Heart Center
        • Contact:
          • Kenya Nasu, MD
        • Principal Investigator:
          • Kenya Nasu, MD
    • Chiba
      • Urayasu, Chiba, Japan, 279-0021
        • Not yet recruiting
        • Juntendo University Urayasu Hospital
        • Contact:
          • Ken Yokoyama
        • Principal Investigator:
          • Ken Tokoyama, MD
    • Fukuoka
      • Kitakyushu, Fukuoka, Japan, 802-8555
        • Not yet recruiting
        • Kokura Memorial Hospital
        • Contact:
          • Shinichi Shirai
        • Principal Investigator:
          • Shinichi Shirai, MD
    • Fukushima
      • Koriyama, Fukushima, Japan, 963-8501
        • Not yet recruiting
        • Hoshi general hospital
        • Contact:
          • Yuichi Ujiie
        • Sub-Investigator:
          • Yuichi Ujiie, MD
      • Koriyama, Fukushima, Japan, 963-8563
        • Not yet recruiting
        • Southern Tohoku Research Institute for Neuroscience
        • Contact:
          • Mitsuru Muto
        • Principal Investigator:
          • Muto Mitsuru, MD
    • Gunma
      • Maebashi, Gunma, Japan, 371-0004
        • Not yet recruiting
        • Gunma prefectural cardiovascular center
        • Contact:
          • Ren Kawaguchi
        • Principal Investigator:
          • Ren Kawaguchi, MD
      • Maebashi, Gunma, Japan, 371-8511
        • Not yet recruiting
        • Gunma University Hospital
        • Contact:
          • Ryuichi Funada
        • Principal Investigator:
          • Ryuichi Funada, MD
      • Ota, Gunma, Japan, 373-8585
        • Not yet recruiting
        • Ota Memorial Hospital
        • Contact:
          • Hidetoshi Anzai
        • Principal Investigator:
          • Hidetoshi Anzai, MD
    • Hokkaido
      • Eniwa, Hokkaido, Japan, 061-1395
        • Not yet recruiting
        • Megumino Hospital
        • Contact:
          • Noriko Makiguchi
        • Principal Investigator:
          • Noriko Makiguchi, MD
      • Monbetsu, Hokkaido, Japan, 099-0404
        • Not yet recruiting
        • JA Hokkaido Engaru Kosei General Hospital
        • Contact:
          • Takahide Suzuki
        • Principal Investigator:
          • Takahide Suzuki, MD
      • Nayoro, Hokkaido, Japan, 096-8511
        • Not yet recruiting
        • Nayoro City General Hospital
        • Contact:
          • Masaru Yamaki
        • Principal Investigator:
          • Masaru Yamaki, MD
      • Sapporo, Hokkaido, Japan, 007-0849
        • Not yet recruiting
        • Sapporo Cardio Vascular Clinic
        • Contact:
          • Yoshifumi Kashima
        • Principal Investigator:
          • Yoshifumi Kashima, MD
    • Hyogo
      • Amagasaki, Hyogo, Japan, 660-8511
        • Not yet recruiting
        • Kansai Rosai Hospital
        • Contact:
          • Masaki Awata
        • Principal Investigator:
          • Masaki Awata, MD
      • Kakogawa, Hyogo, Japan, 685-0115
        • Not yet recruiting
        • Kakogawa East City Hospital
        • Contact:
          • Makoto Kadotani
        • Principal Investigator:
          • Makoto Kadotani, MD
      • Kobe, Hyogo, Japan, 650-0017
        • Not yet recruiting
        • Kobe University Hospital
        • Contact:
          • Toshiro Shinke
        • Principal Investigator:
          • Toshiro Shinke, MD
    • Ibaragi
      • Tsukuba, Ibaragi, Japan, 305-8558
        • Not yet recruiting
        • Tsukuba Medical Center Hospital
        • Contact:
          • Hidetaka Nishina
        • Principal Investigator:
          • Hidetaka Nishina, MD
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 222-0036
        • Not yet recruiting
        • Yokohama Rosai Hospital
        • Contact:
          • Kazuhiko Yumoto
        • Principal Investigator:
          • Kazuhiko YUmoto, MD
      • Yokohama, Kanagawa, Japan, 231-8682
        • Not yet recruiting
        • Yokohama City Minato Red Cross Hospital
        • Contact:
          • Tsukasa Shimura
        • Principal Investigator:
          • Tsukasa Shimura, MD
    • Kyoto
      • Uji, Kyoto, Japan, 611-0025
        • Not yet recruiting
        • Daini Okamoto General Hospital
        • Contact:
          • Masaki Tanabe
        • Principal Investigator:
          • Masaki Tanabe, MD
    • Nagano
      • Matsumoto, Nagano, Japan, 390-8505
        • Not yet recruiting
        • Matsumoto Kyoritsu Hospital
        • Contact:
          • Hidetoshi Abe
        • Principal Investigator:
          • Hidetoshi Abe, MD
    • Osaka
      • Izumisano, Osaka, Japan, 598-8577
        • Not yet recruiting
        • Rinku General Medical Center
        • Contact:
          • Yoshihiro Takeda
        • Principal Investigator:
          • Yoshihiro Takeda, MD
      • Takatsuki, Osaka, Japan, 569-0852
        • Not yet recruiting
        • Hokusetsu General Hospital
        • Contact:
          • Wataru Nagamatsu
        • Principal Investigator:
          • Wataru Nagamatsu, MD
    • Saitama
      • Kasukabe, Saitama, Japan, 344-0035
        • Not yet recruiting
        • Shuwa General Hospital
        • Contact:
          • Ryo Goto
        • Principal Investigator:
          • Ryo Goto, MD
      • Kasukabe, Saitama, Japan, 344-0063
        • Not yet recruiting
        • Kasukabe Chuo General Hospital
        • Contact:
          • Satoru Tohara
        • Principal Investigator:
          • Satoru Tohara, MD
      • Toda, Saitama, Japan, 335-0023
        • Not yet recruiting
        • TODA CHUO General Hospital
        • Contact:
          • Yuichi Kobori
        • Principal Investigator:
          • Yuichi Kobori, MD
    • Shizuoka
      • Hamamatsu, Shizuoka, Japan, 433-8558
        • Not yet recruiting
        • Seirei Mikatahara General Hospital
        • Contact:
          • Yasuyo Takeuchi
        • Principal Investigator:
          • Yasuyo Takeuchi, MD
    • Tokyo
      • Adachi-ku, Tokyo, Japan, 120-0006
        • Not yet recruiting
        • Ayase heart hospital
        • Contact:
          • Hidenari Hozawa
        • Principal Investigator:
          • Hidenari Hozawa, MD
      • Edogawa-ku, Tokyo, Japan, 134-0086
        • Not yet recruiting
        • Tokyo Rinkai Hospital
        • Contact:
          • Motoyuki Onikura
        • Principal Investigator:
          • Motoyuki Onikura, MD
      • Itabashi-ku, Tokyo, Japan, 174-0051
        • Not yet recruiting
        • Itabashi Chuo Medical Center
        • Contact:
          • Hiroshi Ota
        • Principal Investigator:
          • Hiroshi Ota, MD
      • Katsushika-ku, Tokyo, Japan, 125-8506
        • Not yet recruiting
        • Katsushika Medical Center
        • Contact:
          • Yoshiki Uehara
        • Principal Investigator:
          • Yoshiki Uehara, MD
      • Kita-ku, Tokyo, Japan, 115-0053
        • Not yet recruiting
        • Tokyo-kita Social Insurance Hospital
        • Contact:
          • Yuya Nakagawa
        • Principal Investigator:
          • Yuya Nakagawa, MD
      • Minato-ku, Tokyo, Japan, 106-0031
        • Not yet recruiting
        • The Cardiovascular Institute
        • Contact:
          • Yuji Oikawa
        • Principal Investigator:
          • Yuji Oikawa, MD
      • Nakano-ku, Tokyo, Japan, 164-8541
        • Not yet recruiting
        • Tokyo Metropolitan Police Hospital
        • Contact:
          • Masatoshi Suzuki
        • Principal Investigator:
          • Masatoshi Suzuki, MD
      • Shibuya-ku, Tokyo, Japan, 150-0013
        • Not yet recruiting
        • Tokyo Metropolitan Hiroo Hospital
        • Contact:
          • Yasuhiro Tanabe
        • Principal Investigator:
          • Yasuhiro Tanabe, MD
      • Shinagawa-ku, Tokyo, Japan, 141-8625
        • Not yet recruiting
        • NTT Medical Center Tokyo
        • Contact:
          • Masashiro Matsushita
        • Principal Investigator:
          • Masashiro Matsushita, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. A patient with ischemic heart disease including stable angina pectoris and acute coronary syndrome
  2. Male or non-pregnant female

  3. Key lesion inclusion criteria as follows

    1. Multi-vessel diseases
    2. Long lesion (lesion length >30mm by visual estimation)
    3. Small vessel disease (reference diameter <2.5mm by visual estimation)
    4. Bifurcation lesion
    5. Ostial lesion
    6. Calcified lesion
    7. Protected or non-protected left main trunk disease
    8. Chronic total occlusion
    9. In stent restenosis of bare metal stent or everolimus-eluting stent

Exclusion Criteria:

  1. Hypersensitivity to cobalt chromium, everolimus, heparin, aspirin, ticlopidine, clopidogrel or X-ray contrast media.
  2. Serum creatinine level >3.0 mg/dL
  3. Other concomitant disease or medical condition that could impact patient/procedural outcomes, such as history of bleeding diathesis or cancer within 5 years.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: platinum chromium everolimus-eluting stent
Device: platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Major adverse cardiac event including cardiac death, myocardial infarction, and target vessel revascularization
Time Frame: 12 month
12 month

Secondary Outcome Measures

Outcome Measure
Time Frame
Successful stent delivery with final percent diameter stenosis less than 50% at minimum lumen diameter site
Time Frame: In hospital
In hospital
Target lesion revascularization
Time Frame: 12 month
12 month
Target vessel revascularization
Time Frame: 12 month
12 month
Myocardial infarction
Time Frame: 24 month
24 month
Cardiac death
Time Frame: 24 month
24 month
Major adverse cardiac event including cardiac death, myocardial infarction, and target vessel revascularization
Time Frame: 24 month
24 month
Stent thrombosis (acute, sub-acute, late,and very late) defined by Academic Research Consortium (ARC)
Time Frame: 24 month
24 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The PCI Guideline Research Society

Investigators

  • Principal Investigator: Yuji Oikawa, MD, PhD, The Cardiovascular Institute
  • Principal Investigator: Kenya Nasu, MD, FACC, Toyohashi Heart Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2012

Primary Completion (Anticipated)

December 1, 2013

Study Completion (Anticipated)

December 1, 2015

Study Registration Dates

First Submitted

August 16, 2012

First Submitted That Met QC Criteria

August 21, 2012

First Posted (Estimate)

August 22, 2012

Study Record Updates

Last Update Posted (Estimate)

August 22, 2012

Last Update Submitted That Met QC Criteria

August 21, 2012

Last Verified

August 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SPECIALIST Registry

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe